American Conference Institute (ACI) returns to Chicago to present the second iteration of its Paragraph IV Disputes Master Symposium. On this, the 30th anniversary of the Hatch-Waxman Act, this year’s conference will delve into the evolution of the legal and regulatory intricacies and entanglements which have reshaped ANDA litigation. Factors from new PTO procedures instituted under patent reform to new settlement conundrums under Actavis, and a whole new cadre of Supreme Court patent decisions impacting critical Paragraph IV components such as claim construction, personal jurisdiction, 101 patent eligibility, and extraordinary circumstance are drastically changing the rules of the pharmaceutical patent endgame. This symposium will provide authoritative discussions on all these critical matters and offer valuable insights on how to meet these new challenges head-on.
This symposium—a companion to ACI’s flagship Paragraph IV Disputes conference which takes place in New York each spring—is an advanced forum where WilmerHale Senior Counsel Arthur Gajarsa and other leading Hatch-Waxman litigators representing both brand name and generic pharmaceutical companies will exchange ideas and engage in in-depth audience discussions addressing the complexities, conundrums and challenges which comprise today’s Paragraph IV litigation.